November 2024 Update
💰 “DO NOT TOUCH SMCI STOCK: HERE IS WHY!” 💰
$SMCI Stock Fell -70% After We Alerted This Video: August 6th 2024.
Why I was overwhelmingly bearish? Q4 Revenues: $5.3B, +143% YoY and +38% QoQ, sounds great…right?
How did they manage to make $1.458B more than quarter three and still take home less money after taxes? (Net Income) There was a concern about gross margin of 11.2%, down from 15.5% in Q3 and 17.0% year-over-year. This was the tell to avoid $SMCI stock at all costs…
The Hindenburg article followed three weeks later stating that in 2018, Super Micro was temporarily delisted from Nasdaq for failing to file financial statements. By August 2020, the company was charged by the SEC for “widespread accounting violations,” mainly related to $200+ million in improperly recognized revenue and understated expenses, resulting in artificially elevated sales, earnings and profit margins.
Less than 3 months after paying a $17.5 million SEC settlement, Super Micro began re-hiring top executives that were directly involved in the accounting scandal, per litigation records and interviews with former employees.
Lastly, on 9/30/24 Super Micro Computer says Ernst & Young resigns as auditor.
"We are resigning due to information that has recently come to our attention which has led us to no longer be able to rely on management's and the Audit Committee's representations and to be unwilling to be associated with the financial statements prepared by management," Super Micro quoted EY as saying in a filing with the Securities and Exchange Commission.
Currently the stock is down 61% the past month and over 85.8% down from the all-time high on March 8th. Having to find a new auditor will likely result in the company being delisted to the OTC. If that is the case, we can see a lot more downside in the future…
💰Why I'm BUYING MORE Robinhood ($HOOD) Stock Today!💰
$HOOD is up +105% since 8/8/24 [$16.74 —> $34.32]
Third Quarter 2024 Results
Total net revenues increased 36% year-over-year to $637 million.
Transaction-based revenues increased 72% year-over-year to $319 million, primarily driven by options revenue of $202 million, up 63%, cryptocurrencies revenue of $61 million, up 165%, and equities revenue of $37 million, up 37%.
Net income increased year-over-year to $150 million, or diluted earnings per share (EPS) of $0.17, compared to a net loss of $85 million, or diluted EPS of -$0.09, in Q3 2023.
Net Deposits were $10.0 billion, an annualized growth rate of 29% relative to AUC at the end of Q2 2024. Over the past twelve months, Net Deposits were $39.0 billion, a growth rate of 45% relative to AUC at the end of Q3 2023
Average Revenue Per User (ARPU) increased by 31% year-over-year to $105
Gold Subscribers increased by 860,000 or 65% year-over-year to 2.2 million.
Cash and cash equivalents totaled $4.6 billion compared with $4.9 billion at the end of Q3 2023.
Robinhood Retirement Reaches $11 billion in AUC - In October 2024, Robinhood Retirement reached $11 billion in AUC across nearly one million funded retirement accounts. Offering the first ever IRA with a match, customers have received over $200 million in matches on retirement account transfers and contributions since launching in January 2023
$HOOD is a much different company now from a fundamental standpoint compared to IPO (2021, last cycle). From -$2.17 EPS, now is cash flow positive, $0.17c EPS. Billions in cash, significant institutional presence, and the recent acquisition of Bitstamp, they are poised for massive growth.
Acquiring a global exchange will significantly accelerate Robinhood Crypto’s expansion worldwide. Bitstamp holds over 50 active licenses and registrations globally and will bring in customers across the EU, UK, US and Asia to Robinhood.
Source: Robinhood Reports Third Quarter 2024 Results | Robinhood
💰 I Went ALL IN On The #1 Memecoin Of This Crypto Cycle! 💰
$BRETT is up 150% from 9/4/24. We also reiterated Based Brett in our most recent Newsletter on November 5th
$BRETT is my top crypto investment of this cycle and the only coin I have been extremely vocal about not only on YouTube but especially on RealAvidCapital Twitter.
Recently Coinbase Wallet updated their description of Brett which stated: “Introducing Brett, Pepe's best friend on Base Chain. One of cryptos most significant cultural icons and the mascot of Base Chain. As the Base Chain continues to grow, so too will the potential for $BRETT to thrive and expand its offerings.”
We just saw $PEPE get listed on Coinbase Wednesday November 13th, reaching over $10B in market cap. We believe Brett has $SHIB/$DOGE potential, boasting over 700,000 holders it had a very successful startup as one of the fastest coins to reach $500M market cap.
When the market was in a downtrend, meme stocks were getting destroyed and Coinbase ecosystem volume dried up. Base coins all dropped 80/90%, while $BRETT held stronger than any other coin in the entire ecosystem by far. Brett’s floor was 60-65% down from all-time highs.
Betting on $BRETT is betting on Coinbase to be successful as it makes up for more than 70% of the market cap of meme coins on their platform, and has onboarded HUNDREDS OF THOUSANDS of users to download their application, wallet.
Their monthly active users compared to the competition is incredible and continues to grow with the goal of reaching one billion users. Even 10% of that goal is still 100M users this cycle, showing incredible upside potential.
This is also Coinbase network’s first crypto cycle. It is younger, less adopted, less talked about…FOR NOW. This is exactly the time to bet big on this clear emerging chain.
As we can see below $DEGEN was a much smaller project listed on Base and the public response was incredible. Over the past six weeks has steadily made higher highs reaching over +568%.
💰 6 Reasons This Tiny Biotech Could Surge Later This Month!💰
Gain Therapeutics: $GANX ran over 115% in under four weeks from our newsletter above.
Gain Therapeutics' drug GT-02287 may offer more than just treatment for Parkinson's - it might actually cure it.
How? It fixes a faulty enzyme that causes the disease. By doing this, it helps remove harmful proteins that damage brain cells.
Instead of just easing symptoms, GT-02287 could stop Parkinson's from getting worse in the first place. This means it might prevent the disease rather than just treat it.
Gain Therapeutics is currently trading at a fraction of its potential value.
With a market cap below $44 million, the upside is enormous.
If GT-02287 gets FDA approval and the company reaches a $1 billion valuation, investors could see gains of over +2,300%.
Given the recent acquisitions in the biotech space, with companies being bought for north of $500 million, Gain Therapeutics is positioned perfectly for a similar trajectory.
Take Alpine Immune Sciences (ALPN), for instance, which was acquired by Vertex (VRTX) in April 2024 for a whopping $4.9 billion. Or consider Morphic Holding (MORF), snapped up by Eli Lilly (LLY) in July 2024 for $3.2 billion.
These examples show the enormous potential for value creation in the biotech sector, especially for companies with promising drug candidates like Gain Therapeutics
Click here If you haven’t seen our YouTube video on Gain Therapeutics.
Thank you so much for continuing with us on this investment journey.
We'll be diving deeper into more exciting topics in future newsletters.
If you've found this information valuable and want to stay updated on potential market-moving events and analysis, we invite you to subscribe to our free newsletter by clicking the link below:
By subscribing, you're not just getting stock tips - you're gaining insider access to the next big wave in investing.
We'll keep you ahead of the curve with in-depth analysis, industry insights, and timely updates on catalysts that could send stocks soaring.
Feel free to reach out anytime at info@AvidCapital.co
We personally read every message and your insights help shape our future discussions.
We’re looking forward to continuing this journey with you.
Until next time, stay curious and invest wisely!
Zack & Alex
DISCLAIMER:
By engaging with this email and all Avid Capital Partners content, you acknowledge and agree to the following terms. This is not financial advice. Conduct your own thorough research on all information provided. Avid Capital Partners is a publishing entity offering general information, opinions, and news coverage. We do not offer personalized financial advice and are not financial advisors. Our opinions may not be suitable for all investors and should not be interpreted as specific recommendations to make any particular investment or follow any specific strategy. Use this information at your own risk.
Past performance is not indicative of future results. Any results presented are not typical and should not be considered as such. Actual results can vary significantly due to factors such as experience, skill, risk management practices, market conditions, and the amount of capital invested.
Trading is inherently risky. Most traders in all markets lose money. Most small businesses fail. Do not engage in trading, investing, entrepreneurship, or any other risky endeavors discussed here unless you are fully prepared for the reality that most fail.
We reserve the right to maintain affiliate relationships with advertisers and sponsors.
It is important to note that this content is not paid promotional material. Avid Capital Partners has not received any compensation from the company/companies mentioned for the production or distribution of this information. Our goal is to provide unbiased, independent analysis and commentary based on our own research and insights.
In the interest of full disclosure, we want to inform our readers that Avid Capital Partners and/or its affiliates currently hold a position in the stock(s) mentioned in this content. Our investment in the stock does not influence our analysis or opinions, which are formed independently based on publicly available information and our own research methodologies.
It is crucial to understand that investing in financial markets carries inherent risks, including the potential loss of part or all of your invested capital. The value of investments can fluctuate significantly, and there is no guarantee of profits.
While we may hold positions in certain stocks, we reserve the right to sell our shares at any time without notice. Our decision to buy, hold, or sell any security is subject to change based on market conditions, new information, or other factors.
Always remember that your investment decisions should be based on your own research, financial situation, risk tolerance, and investment goals. We strongly recommend consulting with a qualified financial advisor before making any investment decisions.